{"id":966655,"date":"2026-05-26T07:03:43","date_gmt":"2026-05-26T11:03:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/"},"modified":"2026-05-26T07:03:43","modified_gmt":"2026-05-26T11:03:43","slug":"champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/","title":{"rendered":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI<\/b><\/p>\n<p class=\"bwalignc\"><b><i>World\u2019s highest-field MRI system provides leading disease biology research capabilities<\/i><\/b><\/p>\n<p>BILLERICA, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54540879&amp;newsitemid=20260526760440&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=b766fcbeae6d1a3b854460b47ffc3900\">Bruker Corporation<\/a> announced the commissioning of a novel <b><i>BioSpec\u2122<\/i><\/b> 18 Tesla preclinical MRI, the world\u2019s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\" alt=\"Delivery of BioSpec 18 Tesla MRI to Champalimaud\" \/><\/p>\n<p style=\"font-size:85%\">Delivery of BioSpec 18 Tesla MRI to Champalimaud<\/p>\n<\/div>\n<p>\nInstalled at the Champalimaud Foundation\u2019s preclinical MRI laboratory in Lisbon under the leadership of Professor Noam Shemesh, the BioSpec 18T supports advanced neuroscience and oncology research for <i>in vivo <\/i>studies of cancer, metastasis, brain plasticity and neural activity in preclinical models, while supporting the discovery of novel imaging biomarkers with translational relevance. The 18 Tesla system complements Champalimaud\u2019s existing 16.4 Tesla (700 MHz) vertical-bore MRI\/NMR and 9.4 Tesla horizontal-bore MRI.<\/p>\n<p>\n\u201cWe are very excited to explore the full research potential of this novel and unique 18 Tesla system to advance our understanding of biological mechanisms in healthy and diseased conditions,\u201d said Prof. Noam Shemesh, Principal Investigator at Champalimaud. \u201cWe will use its ultra-high field and sensitivity to enable investigations of microstructure and localized metabolic dynamics in the brain and in cancer.\u201d<\/p>\n<p>\n\u201cProviding leading researchers with ultra-high field MRI is a key part of Bruker\u2019s mission in preclinical imaging,\u201d said Dr. Tim Wokrina, Product Manager MRI at Bruker. \u201cWe are very pleased to support the Champalimaud Foundation\u2019s neuroscience and oncology research programs.\u201d<\/p>\n<p>\nFor more information visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bruker.com%2Fproducts%2Fmr%2Fpreclinical-mri.html&amp;esheet=54540879&amp;newsitemid=20260526760440&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.bruker.com%2Fproducts%2Fmr%2Fpreclinical-mri&amp;index=2&amp;md5=b4978023fdda8689d0cf71174a6f4004\">https:\/\/www.bruker.com\/products\/mr\/preclinical-mri<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffchampalimaud.org%2Fnews%2Fchampalimaud-foundation-installs-powerful-mri-scanner-setting-new-standards-high-field-imaging&amp;esheet=54540879&amp;newsitemid=20260526760440&amp;lan=en-US&amp;anchor=https%3A%2F%2Ffchampalimaud.org%2Fnews%2Fchampalimaud-foundation-installs-powerful-mri-scanner-setting-new-standards-high-field-imaging&amp;index=3&amp;md5=fe2ab9f86a0eed62bc491273f00e0e12\">https:\/\/fchampalimaud.org\/news\/champalimaud-foundation-installs-powerful-mri-scanner-setting-new-standards-high-field-imaging<\/a><\/p>\n<p><b>About Bruker Corporation \u2013 Leader of the Post-Genomic Era <\/b>(Nasdaq: BRKR)<\/p>\n<p>\nBruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker\u2019s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54540879&amp;newsitemid=20260526760440&amp;lan=en-US&amp;anchor=www.bruker.com&amp;index=4&amp;md5=3b023a2422e991dd9bdab694cbb15f75\">www.bruker.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260526760440r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Joe Kostka<br \/>\n<br \/>Director &#8211; Investor Relations<br \/>\n<br \/>Bruker Corporation<br \/>\n<br \/>T: +1 978 313-5800<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:Investor.Relations@bruker.com\">Investor.Relations@bruker.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Markus Ziegler<br \/>\n<br \/>Sr. Director and Head of Group Marketing<br \/>\n<br \/>Bruker BioSpin<br \/>\n<br \/>T: +49 172 3733531<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:pr@bruker.com\">pr@bruker.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States Portugal North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Neurology Philanthropy Biotechnology Radiology Health Foundation Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/3\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Delivery of BioSpec 18 Tesla MRI to Champalimaud<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813300\/3\/BioSpec180-USR_front.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">BioSpec 18 Tesla preclinical MRI magnet<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/772973\/3\/Bruker_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI World\u2019s highest-field MRI system provides leading disease biology research capabilities BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation announced the commissioning of a novel BioSpec\u2122 18 Tesla preclinical MRI, the world\u2019s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/ Delivery of BioSpec 18 Tesla MRI to Champalimaud Installed at the Champalimaud Foundation\u2019s preclinical MRI laboratory in Lisbon &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI World\u2019s highest-field MRI system provides leading disease biology research capabilities BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation announced the commissioning of a novel BioSpec\u2122 18 Tesla preclinical MRI, the world\u2019s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/ Delivery of BioSpec 18 Tesla MRI to Champalimaud Installed at the Champalimaud Foundation\u2019s preclinical MRI laboratory in Lisbon &hellip; Continue reading &quot;Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T11:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI\",\"datePublished\":\"2026-05-26T11:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/\"},\"wordCount\":549,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260526760440\\\/en\\\/2813299\\\/4\\\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/\",\"name\":\"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260526760440\\\/en\\\/2813299\\\/4\\\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\",\"datePublished\":\"2026-05-26T11:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260526760440\\\/en\\\/2813299\\\/4\\\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260526760440\\\/en\\\/2813299\\\/4\\\/Delivery_of_BioSpec_at_Champalimaud_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/","og_locale":"en_US","og_type":"article","og_title":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk","og_description":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI World\u2019s highest-field MRI system provides leading disease biology research capabilities BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation announced the commissioning of a novel BioSpec\u2122 18 Tesla preclinical MRI, the world\u2019s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260526760440\/en\/ Delivery of BioSpec 18 Tesla MRI to Champalimaud Installed at the Champalimaud Foundation\u2019s preclinical MRI laboratory in Lisbon &hellip; Continue reading \"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-26T11:03:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI","datePublished":"2026-05-26T11:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/"},"wordCount":549,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/","name":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg","datePublished":"2026-05-26T11:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260526760440\/en\/2813299\/4\/Delivery_of_BioSpec_at_Champalimaud_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/champalimaud-foundations-neuroscience-and-oncology-research-benefits-from-18-tesla-ultra-high-field-mri\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Champalimaud Foundation\u2019s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}